Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Succinylated gelatin is a chemically modified gelatin-polypeptide colloid used as an intravenous plasma-volume substitute. It exerts a physical, non-receptor-mediated effect: retained colloid molecules increase intravascular oncotic pressure and transiently expand circulating plasma volume, supporting venous return, cardiac output, blood pressure, and tissue perfusion during volume loss or perioperative hemodilution. Standard Gelofusine products are 4% succinylated gelatin solutions for infusion; regulatory product information identifies use for replacement of fluid and blood losses, prevention of anesthesia-associated hypotension, and support during extracorporeal circulation. ([medicines.org.uk](https://www.medicines.org.uk/emc/files/pil.15140.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on succinylated gelatin.